Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2025)
Historic Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $353.4 million.
- Amylyx Pharmaceuticals' Current Assets rose 4408.33% to $353.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.4 million, marking a year-over-year increase of 4408.33%. This contributed to the annual value of $189.4 million for FY2024, which is 5923.27% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Current Assets of $353.4 million as of Q3 2025, which was up 4408.33% from $186.9 million recorded in Q2 2025.
- Amylyx Pharmaceuticals' 5-year Current Assets high stood at $464.7 million for Q4 2023, and its period low was $105.0 million during Q4 2021.
- Over the past 5 years, Amylyx Pharmaceuticals' median Current Assets value was $296.1 million (recorded in 2022), while the average stood at $299.0 million.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' Current Assets soared by 26410.61% in 2022, and later tumbled by 5923.27% in 2024.
- Amylyx Pharmaceuticals' Current Assets (Quarter) stood at $105.0 million in 2021, then surged by 264.11% to $382.1 million in 2022, then grew by 21.6% to $464.7 million in 2023, then plummeted by 59.23% to $189.4 million in 2024, then soared by 86.55% to $353.4 million in 2025.
- Its last three reported values are $353.4 million in Q3 2025, $186.9 million for Q2 2025, and $216.1 million during Q1 2025.